Clinical trials: Hyperlipoproteinemia (a)
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Subjects With Hyperlipidemia, Dyslipidemia
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
- Trial name
- ANITSCHKOW (NCT02729025)
- Testing
- Evolocumab
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Hyperlipidemia
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein…
- Trial name
- RUTHERFORD-2 (NCT01763918)
- Testing
- Evolocumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 331 people
- Sponsor
- Amgen
HIV, Hyperlipidemia
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients
The aim of the study is to compare the effects of coadministration of ezetimibe 10 mg/die + fenofibrate 200 mg/die versus pravastatin 40 mg/die monotherapy in HIV-infected patients treated with protease inhibitors.
- Conditions
- HIV, Hyperlipidemia, HIV Infections
- Trial name
- NCT00843661
- Testing
- ezetimibe, fenofibrate, pravastatin
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi
Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia. A total of 156 Participants were actually enrolled
- Trial name
- NCT07421232
- Testing
- Inclisiran (Leqvio®) 300mg
- Where
- China
- Volunteers
- 156 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
This is a treatment program for the use of plozasiran in adults (AROAPOC3-EAP-002) and adolescents (AROAPOC3-EAP-003) with familial chylomicronemia syndrome (FCS) as well as in adults (AROAPOC3-EAP-004) with high risk severe…
- Trial name
- NCT06796426
- Testing
- Plozasiran
- Where
- United States
- Sponsor
- Arrowhead Pharmaceuticals
Hyperlipidemia, Diabetes Mellitus, Type 2
Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus
The study will investigate the effects of atorvastatin on the concentrations of small, dense LDL and HDL subfractions in patients with diabetes and the underlying mechanisms of these effects.
- Conditions
- Hyperlipidemia, Diabetes Mellitus, Type 2, Non-Insulin Dependent Diabetes Mellitus
- Trial name
- ALPIN (NCT00640549)
- Testing
- Atorvastatin
- Where
- 14 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension With Hyperlipidemia
Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia
To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia
- Trial name
- NCT03536598
- Testing
- Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg, Amlodipine 10 mg + Valsartan 160 mg, Valsartan 160 mg + Rosuvastatin 20 mg
- Volunteers
- 203 people
- Sponsor
- HK inno.N Corporation
Hyperlipidemia, Medication Nonadherence
AdLip: Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medication
Investigators hypothesize that the use of a human coach-supported digital/AI personal health assistant (app) will improve adherence to cholesterol-lowering medications (statins with or without ezetimibe) among patients with…
- Trial name
- AdLip (NCT06614049)
- Testing
- Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications
- Where
- 2 sites in Singapore
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Heart Diseases
Exercise as a Modulator of Immune Risk Factors for Ischemic Heart Disease
A before and after study involving 43 adult subjects at risk of having ischemic heart disease. Subjects underwent 6 months of supervised moderate intensity aerobic and resistive exercise training.
- Trial name
- NCT04195932
- Testing
- Exercise training
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- East Tennessee State University
Type 2 Diabetes
Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes
Many patients with type 2 diabetes have difficulty attaining cholesterol goals, partly due to the recommendations for fasting measurements that may not be practical in the typical clinical setting.
- Trial name
- NCT00287404
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina
Homozygous Familial Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial…
- Trial name
- NCT06723652
- Testing
- SHR-1918
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Hyperlipidemia
The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia
This is a randomized, double-blind, placebo- controlled phaseⅠb/Ⅱclinical study. Totally 108 subjects are planned to enrolled with 36 subjects in three low-dose groups (group 1, group 2 and group 3) and 72 subjects in three…
- Trial name
- NCT03944109
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Familial Hypercholesterolemia, Atherosclerosis
Familial Hypercholesterolemia in Turkey (A-HIT2)
A-HIT2, is also designed as a National FH registry. At least 1000 FH patients will be recruited from 30 outpatient clinics representing the 12 Nuts statistical Regions in Turkey proportional to the 2015 Turkey's Population…
- Trial name
- A-HIT2 (NCT03110250)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Ege University
LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms
In this study, 102 patients will be evenly randomized into two groups: one set to receive omega-3 fatty acids and the other a placebo.
- Conditions
- LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia, Triglyceride Storage Type I or II Disease
- Trial name
- SOLIPARG (NCT06154408)
- Testing
- omega-3 fatty acids
- Where
- Russia
- Volunteers
- 102 people
- Sponsor
- S.LAB (SOLOWAYS)
Familial Hypercholesterolemia
Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is an autosomal codominant single gene disorder caused by mutations in the LDL receptor gene (LDLR) that disrupt the normal clearance of LDL particles from the plasma.
- Trial name
- NCT02225340
- Where
- Canada
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Laval University
Dyslipidemias, Familial Hypercholesterolemia
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers
This is a randomized, double blinded, phase 1 study. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose of VSA003 in healthy adult volunteerst
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT05851066
- Testing
- VSA003, 0.9% NaCl
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Visirna Therapeutics HK Limited
Hyperlipidemia
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
- Trial name
- ACTFAST SWISS (NCT00136942)
- Testing
- Atorvastatin
- Where
- 20 sites in Switzerland
- Volunteers
- 370 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia, Statin-Associated Myopathy
Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance
This study will examine the effect of red yeast rice extract compared to pravastatin on muscle related complaints in individuals with high cholesterol who have previously been unable to tolerate statin medications due to muscle…
- Trial name
- NCT00639223
- Testing
- Red Yeast Rice, Pravastatin, Lifestyle modification program
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Pennsylvania
Homozygous Familial Hypercholesterolemia
A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
This study was a Phase III,A two-part (double-blind placebo-controlled/open-label) multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in subjects with homozygous familial hypercholesterolemia (HoFH).
- Trial name
- ORION-5 (NCT03851705)
- Testing
- Inclisiran Sodium for injection
- Where
- 13 sites in Hong Kong, Israel and 6 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals